A study by Enrica Borsi et al. indicated that EZN-2968 targets HIF-1α mRNA suppression to cause a metabolic shift that leads to increased production of ATP by oxidative phosphorylation and affected apoptosis to improve multiple myeloma treatment [53,54]. Here, HIF1A is linked to plasma cell myeloma.